Prognostic Factors in Patients with Malignant Pleural Mesothelioma

Aleksey N. Kurchenkov, MD; Vyacheslav P. Kurchin, MD, PhD, ScD; Vladimir V. Zharkov, MD, PhD, ScD

N.N. Alexandrov National Cancer Centre of Belarus, Minsk, Belarus

*Corresponding author: Aleksey N. Kurchenkov, MD, researcher of the thoracic oncopathology department with the anesthesiology group of N.N. Alexandrov National Cancer Centre of Belarus Minsk, Belarus E-mail: akurchenkov@mail.ru

Published: March 25, 2015. DOI: 10.21103/Article5(1)_CR1

Abstract: 

The aim of the present study was to examine the factors of prognosis in patients with malignant pleural mesothelioma (MPM) after combined and multimodality treatment, including the prognostic significance of preoperative intrapleural perfusion hyperthermo-chemotherapy (IPHC).

Material and Methods: The study included 20 patients (11 men and 9 women) aged from 30 to 70 years (mean age 51.9±8.5 years) who underwent surgical treatment for MPM. The diagnosis of MPM was verified by immunohistochemical data. The patients were divided into two groups. Group 1 included 9 patients who underwent combined treatment that included the extrapleural pneumonectomy (EPP) and 4 courses of adjuvant chemotherapy. Group 2 included 11 patients who received multimodality treatment (IPHC, EPP, and 4 courses of adjuvant chemotherapy). All patients were followed prospectively at three-monthly intervals for the first year and six-monthly thereafter until the last time of contact or death. Statistical analysis was performed by using Kaplan-Meier method and the log-rank test. Cox-regression model was used for multivariate analysis.

Results: Patient’s age over 60 years and the sarcomatoid type of the tumor can be regarded as prognostic factors for poor survival in patients with MPM who underwent EPP. Application of IPHC as a part of a multimodality treatment enhances the survivability of MPM patients.

Keywords: 
malignant pleural mesothelioma; extrapleural pneumonectomy; intrapleural perfusion hyperthermo-chemotherapy; multimodality treatment.
References: 
  1. Milano M T, Zhang H. Malignant pleural mesothelioma: a population-based study of survival. J Thorac Oncol 2010; 5(11):1841-8.
  2. Vogelzang N J, Rusthoven J J, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003; 21(14): 2636-44.
  3. Yan TD,  Boyer M, Tin M,  McLean J, Banon P G, McCaughan BC. Treatment failure after extrapleural pneumonectomy for malignant pleural mesothelioma. J Thorac Dis 2009; 1(1):23-8.
  4. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig  KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27(18):3007-13.
  5. Weder W, Opitz I. Multimodality therapy for malignant pleural mesothelioma. Ann Cardiothorac Surg 2012; 1(4):502-7.
  6. Kaplan E L, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958; 53:457-81.
  7. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966; 50(3):163-70.
  8. Cox D R. Regression models and life tables. J R Stat Soc (B) 1972; 34:187–229.
  9. Lavnikova GA. Some regularities of radiation pathomorphism of human tumors and their practical use. Bull Acad Med Sci 1976; 6:13-9.[Article in Russian].
  10. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Strauss GM, Corson JM, et al. Resection margins, extrapleural nodal status, and cell type determine postoperative long-term survival in trimodality therapy of malignant pleural mesothelioma: results in 183 patients. J Thorac Cardiovasc Surg 1999; 117(1): 54-63.
  11. Flores RM, Pass HI, Seshan VE, Dycoco J, Zakowski M, Carbone M, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg 2008; 135(3): 620-6.
  12. de Perrot M, Feld R, Cho BC, Bezjak A, Anraku M, Burkes R, et al. Trimodality therapy with induction chemotherapy followed by extrapleural pneumonectomy and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma. J Clin Oncol 2009; 27(9):1413-8.
  13. Rusch VW, Giroux D, Kennedy C, Ruffini E, Canqir AK, Rice D, et al. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol 2012; 7(11):1631-9.
  14. Pass HI, Giroux D, Kennedy C, Ruffini E, Canqir AK, Rice D, et al. Supplementary prognostic variables for pleural mesothelioma: A report from the IASLC Staging Committee. J Thorac Oncol 2014; 9(6):856-64.
  15. Koga S, Hamazoe R, Maeta M, Shimizu N, Kanayama H, Osaki Y. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 1984; 44(5):1840-2.

The fully formatted PDF version is available.  

Download Article

Int J Biomed. 2015; 5(1):7-10. © 2015 International Medical Research and Development Corporation. All rights reserved.